Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Considers Capping SPF Values At 50+ Despite Efficacy Data

This article was originally published in The Tan Sheet

Executive Summary

FDA might cap sun protection values at 50 or 50+ so as not to mislead consumers about the clinical benefit of sunscreens with higher SPF values, according to a proposed rule.

You may also be interested in...



Consumer Reports Lathers On More Criticism Of Sunscreen SPF Claims

The annual bad marks for sunscreen brands SPF claims from Consumer Reports could be due to CR's nonconformity with FDA-prescribed test guidelines or could signal testing failures or other compliance problems in the industry. In any event, companies retest sunscreen formulas to validate their claims.

Consumer Reports Lathers On More Criticism Of Sunscreen SPF Claims

The annual bad marks for sunscreen brands SPF claims from Consumer Reports could be due to CR's nonconformity with FDA-prescribed test guidelines or could signal testing failures or other compliance problems in the industry. In any event, companies retest sunscreen formulas to validate their claims.

Coppertone ‘Assurance Assessment’ Anticipates Criticism From Sunscreen Reviews

Bayer shares results from a consulting firm's assessment of its operations, procedures and testing at the root of Coppertone SPF claims and other labeling aspects. The firm could get in front of a conversation that tends to arise this time of year regarding sunscreen safety, effectiveness and truthfulness in marketing.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS105121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel